These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38648034)

  • 21. The Role of Dermal Fibroblasts in Nevoid Basal Cell Carcinoma Syndrome Patients: An Overview.
    Bellei B; Caputo S; Carbone A; Silipo V; Papaccio F; Picardo M; Eibenschutz L
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
    PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the role of TORC1/2 in multiple myeloma.
    Maiso P; Liu Y; Morgan B; Azab AK; Ren P; Martin MB; Zhang Y; Liu Y; Sacco A; Ngo H; Azab F; Quang P; Rodig SJ; Lin CP; Roccaro AM; Rommel C; Ghobrial IM
    Blood; 2011 Dec; 118(26):6860-70. PubMed ID: 22045983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGFβ- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR).
    Goc A; Choudhary M; Byzova TV; Somanath PR
    J Cell Physiol; 2011 Nov; 226(11):3004-13. PubMed ID: 21302298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
    Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
    J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
    Koletsa T; Petrakis G; Karayannopoulou G; Euvrard S; Kanitakis J
    Anticancer Res; 2018 Jun; 38(6):3319-3322. PubMed ID: 29848679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of calretinin in odontogenic keratocysts and basal cell carcinomas: A study of sporadic and Gorlin-Goltz syndrome-related cases.
    Cesinaro AM; Burtini G; Maiorana A; Rossi G; Migaldi M
    Ann Diagn Pathol; 2020 Apr; 45():151472. PubMed ID: 31982676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.
    Stockfleth E; Ulrich C; Hauschild A; Lischner S; Meyer T; Christophers E
    Eur J Dermatol; 2002; 12(6):569-72. PubMed ID: 12459530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
    Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
    J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
    Bartoš V
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.